Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Acute myeloid leukaemia.

Elihu Estey1, Hartmut Döhner

  • 1Leukemia Department, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA. ehestey@mdanderson.org

Lancet (London, England)
|November 28, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Probability of remission with reinduction with 7+3 versus high-dose cytarabine: analysis of SWOG trial S1203.

Leukemia·2025
Same author

Comparison between measurable residual disease relapse and morphologic relapse in acute myeloid leukemia and high-grade myeloid neoplasms.

Leukemia·2023
Same author

Characteristics and outcome of acute myeloid leukemia with uncommon retinoic acid receptor-alpha (RARA) fusion variants.

Blood cancer journal·2021
Same author

Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal.

Blood·2021
Same author

Correction to: Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation.

Bone marrow transplantation·2021
Same author

Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation.

Bone marrow transplantation·2021

Acute myeloid leukaemia (AML) is a common adult cancer. Genetic defects impact AML treatment outcomes, with elderly patients facing poor prognoses despite advances in targeted therapies.

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Acute myeloid leukaemia (AML) is a prevalent malignant myeloid disorder in adults, typically diagnosed around age 70.
  • Genetic mutations are key determinants of chemotherapy response and patient outcomes in AML.
  • Significant treatment progress exists for younger adults, but elderly patients experience dismal survival rates due to comorbidities and disease biology.

Purpose of the Study:

  • To review the current understanding of AML pathogenesis, focusing on genetic factors.
  • To highlight the challenges in treating elderly AML patients.
  • To discuss the potential of targeted therapies in improving AML cure rates.

Main Methods:

  • Review of recent molecular biology research in AML.

Related Experiment Videos

  • Analysis of treatment outcomes comparing different age groups.
  • Assessment of emerging targeted therapy approaches.

    • Main Results:

    • Genetic defects are crucial in AML progression and treatment response.
    • Elderly AML patients have poor prognoses compared to younger individuals.
    • Targeted therapies represent a promising avenue for increasing AML cure rates.

    Conclusions:

    • Understanding AML's molecular pathogenesis is vital for developing effective treatments.
    • Addressing age-related factors and disease biology is essential for improving elderly patient outcomes.
    • Targeted therapies hold significant promise for enhancing AML treatment efficacy and survival rates.